KPTI Karyopharm Therapeutics Inc
- Stocks
- Healthcare
- NASDAQ: KPTI
Price (delayed)
$5.36
Market cap
$91.39M
P/E Ratio
N/A
Dividend/share
N/A
EPS
-$14.61
Enterprise value
$249.79M
Relative Growth:
Rel. Growth:
24
Relative Strength:
Rel. Strength:
28
Relative Valuation:
Rel. Valuation:
38
Relative Profitability:
Rel. Profitability:
20
Karyopharm Therapeutics Inc. is a commercial-stage pharmaceutical company pioneering novel cancer therapies and dedicated to the discovery, development, and commercialization of novel first-in-class drugs directed against nuclear export and related
Highlights
Karyopharm Therapeutics's quick ratio has plunged by 67% YoY but it has increased by 4.7% from the previous quarter
The company's gross profit fell by 3.9% YoY but it rose by 3.4% QoQ
The equity has plunged by 69% YoY and by 13% from the previous quarter
The net income has contracted by 42% YoY
Key stats
What are the main financial stats of KPTI
Market
Valuations
Earnings
Shares outstanding
17.05M
Market cap
$91.39M
Enterprise value
$249.79M
Price to earnings (P/E)
N/A
Price to book (P/B)
N/A
Price to sales (P/S)
0.33
PEG
N/A
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
1.75
Revenue
$142.53M
Gross profit
$136.73M
Operating income
-$104.14M
Net income
-$124.62M
EBIT
-$80.19M
EBITDA
-$79.83M
Free cash flow
-$89.3M
Per share
Balance sheet
Liquidity
EPS
-$14.61
EPS diluted
-$14.51
Free cash flow per share
-$10.3
Book value per share
-$31.05
Revenue per share
$16.44
TBVPS
$11.1
Total assets
$96.23M
Total liabilities
$365.49M
Debt
$196.42M
Equity
-$269.26M
Working capital
$2.59M
Debt to equity
-0.73
Current ratio
1.03
Quick ratio
0.9
Net debt/EBITDA
-1.98
Margins
Efficiency
Dividend
EBITDA margin
-56%
Gross margin
95.9%
Net margin
-87.4%
Operating margin
-73.1%
Return on assets
-101.1%
Return on equity
N/A
Return on invested capital
-45%
Return on capital employed
-883.6%
Return on sales
-56.3%
Dividend yield
N/A
DPS
N/A
Payout ratio
N/A
KPTI stock price
How has the Karyopharm Therapeutics stock price performed over time
Intraday
-5.13%
1 week
-11.84%
1 month
-15.99%
1 year
-57.73%
YTD
-47.14%
QTD
-18.04%
Financial performance
How have Karyopharm Therapeutics's revenue and profit performed over time
Revenue
$142.53M
Gross profit
$136.73M
Operating income
-$104.14M
Net income
-$124.62M
Gross margin
95.9%
Net margin
-87.4%
KPTI's net margin is down by 48% YoY but it is up by 2.9% from the previous quarter
The net income has contracted by 42% YoY
KPTI's operating income is up by 17% YoY and by 10% QoQ
KPTI's operating margin is up by 14% YoY and by 13% QoQ
Price vs fundamentals
How does KPTI's price correlate with its fundamentals
Growth
What is Karyopharm Therapeutics's growth rate over time
Valuation
What is Karyopharm Therapeutics stock price valuation
P/E
N/A
P/B
N/A
P/S
0.33
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
1.75
The EPS has contracted by 23% YoY
The equity has plunged by 69% YoY and by 13% from the previous quarter
The P/S is 86% lower than the 5-year quarterly average of 2.4 and 18% lower than the last 4 quarters average of 0.4
The revenue has contracted by 4% YoY but it has grown by 3.8% from the previous quarter
Efficiency
How efficient is Karyopharm Therapeutics business performance
KPTI's ROA has shrunk by 145% YoY and by 20% QoQ
Karyopharm Therapeutics's return on invested capital has shrunk by 125% YoY and by 14% QoQ
The ROS has plunged by 53% YoY
Dividends
What is KPTI's dividend
DPS
N/A
Dividend yield
N/A
Payout ratio
N/A
There are no recent dividends present for KPTI.
Financial health
How did Karyopharm Therapeutics financials performed over time
KPTI's total assets is 74% smaller than its total liabilities
Karyopharm Therapeutics's quick ratio has plunged by 67% YoY but it has increased by 4.7% from the previous quarter
The current ratio has plunged by 66% YoY but it has grown by 4% from the previous quarter
KPTI's debt is 173% more than its equity
The equity has plunged by 69% YoY and by 13% from the previous quarter
KPTI's debt to equity is up by 40% year-on-year and by 9% since the previous quarter
All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise specified.